Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 288 participants.
Also called NCT03281538
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 288 participants
- Sponsor
- Registry
-
NCT03281538
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT03281538. Allocation not applicable; no masking; primary purpose treatment. Start 2017-08-14 (actual); primary completion 2020-02-11 (actual). Results posted on 2021-10-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
- Condition
- Uremic Pruritus
- Intervention (Drug)
- CR845
- Lead sponsor
- Cara Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct03281538- Content hash
27bda13ab0aeea89a873464b872cd8cb1cf0e72569fe204a826ca822b81a9b98